Pharmacokinetic profile of cisapride 20 mg after once- and twice-daily dosing

Clinical Therapeutics

Volumn 20, Issue 2, 1998, Pages 292-298

  Zhou, Honghui ^a   Herron, Jerry ^b   Clyde, Christopher ^a   Lee, Peter ^a   Mechlinski, Witold ^a   Pesco Koplowitz, Luana ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Research Solutions LLC   (United States)

Author keywords

Cisapride; Gastroesophageal reflux disease; Heartburn

Indexed keywords

CISAPRIDE; METOCLOPRAMIDE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; TABLET;

EID: 0031746135     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80092-1     Document Type: Article

References (8)

1. Reyntjens A. Rationale for the development of a novel gastrointestinal prokinetic, cisapride. Scand J Gastroenterol Suppl. 1989;165:1-6.
2. Propulsid®. Physicians' Desk Reference®. Montvale, NJ: Medical Economics Co, Inc; 1997:1346-1348.
3. Barone JA, Jessen LM, Colaizzi JL, Bierman RH. Cisapride: A gastrointestinal prokinetic drug. Ann Pharmacother. 1994; 28:488-500.
4. Verlinden M, Bussche GV. Expert report on the efficacy and safety of a new dosing regimen of cisapride, two intakes of 20 mg per day, in reflux oesophagitis. Data on file, Report No. N78112. Janssen Research Foundation; Beerse, Belgium.
5. Data on file. Janssen Research Foundation; Titusville, NJ.
6. McCallum RW. Cisapride: A new class of prokinetic agent. Am J Gastroenterol. 1991;86:135-149.
7. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs. 1994;47:116-152.
8. Greenberg RN. Overview of patient compliance with medication dosing: A literature review. Clin Ther. 1984;6:592-599.